Articles tagged with Drug Candidates
A study published in mAbs reveals that up to one-third of antibody-based drugs exhibit nonspecific binding to unintended targets, a serious concern for patient safety. The Membrane Proteome Array technology helped identify this issue, challenging the long-held belief in absolute antibody specificity.
Researchers from Thomas Jefferson University and the University of Maryland Baltimore developed a promising new vaccine candidate that protects against Lassa fever. The study demonstrated the vaccine effectively prevents severe cases of the disease and death in preclinical animal models, paving the way for research in people.
Johannes Wahl receives EUR 1.5 million ERC Starting Grant to streamline synthesis of nitrogen-containing compounds, accelerating identification of promising drug candidates and tailoring their properties. Late-stage nitrogen insertion enables better adjustment of physical and chemical properties.
A new narrow-spectrum antibiotic, FP 100, has been found to effectively eliminate Fusobacterium nucleatum without harming the oral or gut microbiomes. This breakthrough discovery holds significant implications for treating severe gum disease and preventing related systemic conditions such as colon cancer and Alzheimer's disease.
Researchers investigated peptide clumping behavior using molecular dynamics simulations and AI techniques. They discovered that aromatic amino acids enhance aggregation, while hydrophilic ones inhibit it, offering insights into peptide structure and function.
Researchers have identified two compounds with strong antivirulence activity from actinobacteria in the Arctic Sea, targeting EPEC bacteria that cause severe diarrhea. The compounds inhibit virulence factor formation and binding to host cells, reducing disease severity and potential for resistance.
Researchers have used cryo-electron microscopy to reveal the structural basis of how cells regulate ferritin, a protein that stores iron. This understanding could lead to the development of drugs that block ferritin's interaction with NCOA4, slowing down aggressive cancer cells.
Researchers developed a novel EIT-EVA PCB sensor for non-invasive assessment of drug inhibition on ion channels. The system enables real-time monitoring of ion flow changes in response to drug exposure, offering a faster and more efficient alternative to traditional methods.
Researchers at Hokkaido University have developed a comprehensive derivative synthesis method to find new antimicrobial drugs. They identified eight analogs possessing strong MraY inhibitory and antibacterial activity, with one showing promising effectiveness in mouse infection models.
Researchers at Tampere University analyzed the molecular activity of over 10,000 genes to investigate the efficacy of ZED1227, a transglutaminase 2 inhibitor. The study found that ZED1227 effectively prevented gluten-induced intestinal mucosal damage and inflammation in celiac patients.
Researchers have identified a potent and unique way to kill drug-resistant bacteria using a repurposed compound called LEI-800. The compound targets the bacterial enzyme DNA gyrase, which is essential for bacterial growth and has not been targeted by existing antibiotics.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
A recent study by Bryan Roth and colleagues validated the accuracy of AlphaFold2 in modeling ligand binding sites, leading to promising results for drug discovery. The researchers found that up to 54% of potential compounds interacted successfully with the target proteins, paving the way for new treatments.
Researchers have successfully adapted a modified drug molecule to selectively bind to a protein in bacteria, rather than human cells, making it more effective against bacterial infections. This breakthrough could provide a new avenue for treating antibiotic-resistant bacterial infections.
Researchers at Karolinska Institutet have discovered a new class of drugs that block mitochondrial function and reverse diet-induced obesity, fatty liver, and diabetes in mice. The treatment increased fat metabolism, leading to drastic weight loss and restored glucose tolerance.
A team of researchers from MSU and Harvard Medical School has created a promising vaccine candidate for antibiotic-resistant bacteria. The vaccine targets Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA), with high levels of immunity observed in animal trials.
A new statistical-modeling workflow can quickly identify molecular structures of products formed by chemical reactions, accelerating drug discovery and synthetic chemistry. The workflow also enables the analysis of unpurified reaction mixtures, reducing time spent on purification and characterization.
Researchers at Butantan Institute used phage display to screen 12,000 proteins from Schistosoma mansoni, identifying key parasite peptides targeted by macaque antibodies. This approach has potential for developing candidate vaccines against the disease.
Researchers discovered compounds with untapped therapeutic potential for treating BPH, melanogenesis, and nerve damage. Metformin restored sex hormone homeostasis, epimedin B stimulated pigmentation function, and hydralazine suppressed ferroptosis to aid in axon regeneration.
Researchers from Rutgers University have developed an oral COVID-19 treatment that inhibits disease progression in animals, paving the way for human trials. The treatment, dubbed Jun12682, interferes with viral papain-like protease and shows promise as a potential replacement for Paxlovid.
Researchers found that chlorogenic acid enhances osteoblast proliferation and differentiation, while inhibiting RANKL-induced osteoclastogenesis. Administration of chlorogenic acid antagonizes ovariectomized-induced bone loss in rats.
Researchers have developed a new, synthetic lung surfactant that mimics the functionality of animal-derived formulations. The surfactant has shown promise in reducing surface tension and may offer a cheaper alternative to Infasurf.
Scientists have extracted a powerful antibacterial peptide from African catfish skin mucus, which could help combat antibiotic-resistant bacteria. The peptide, called NACAP-II, has been shown to disrupt bacterial cell membranes at very low concentrations.
A newly developed compound is showing promise as a more effective treatment for human schistosomiasis, an understudied tropical disease caused by parasitic worms. The compound overcomes the limitations of current treatment praziquantel by being effective against the larval stage and resistant strains.
A study published in Nature Metabolism reveals that the diabetes drug metformin and solid foods increase a hunger-reducing factor called Lac-Phe, while sugary drinks have minimal effect. This discovery could lead to new anti-obesity treatments and help explain why liquid calories drive obesity.
Researchers have identified a potential path to eliminate the viral reservoir that prevents people from being completely cured of HIV. A new drug candidate, called a proteolysis targeting chimeras (PROTAC) molecule, triggers the degradation of the Nef protein, which suppresses HIV replication and restores immune system detection. This ...
A new multitasking substance has been identified to prevent and treat both flu and COVID-19 infections concurrently. The long-acting recombinant cytokine protein rhIL-7-hyFc demonstrated therapeutic and preventive effects against various respiratory diseases, including COVID-19, influenza virus, and respiratory syncytial virus.
Researchers developed a new recombinant flu vaccine called Hexaplex, which provided superior protection against H1N1 and H3N2 viruses in animal models. The vaccine's combination of six proteins from different groups resulted in strong antibody production and T-cell activation, offering broader immunity.
Researchers have developed a new class of antibiotics that can overcome drug-resistant bacteria by targeting the physical and functional integrity of the bacterial cell wall. This could be a game-changer in treating infections, particularly those caused by resistant strains.
Researchers discovered two compounds in female ginseng with potent anti-osteoporotic activity and blocked key molecular pathways involved in bone loss. The study opens up possibilities for new osteoporosis treatments based on the compound, whether in its current form or as a structural template.
ATH-1105, a small molecule positive modulator of the neurotrophic HGF system, demonstrates significant neuroprotective effects and extends survival in preclinical models of ALS. The study highlights the therapeutic potential of ATH-1105 in slowing or stopping neurodegeneration.
The lack of synergy between academia and industry in drug discovery hinders the development of effective treatments. Researchers discuss why many therapeutic molecules fail to reach clinical trials despite pre-clinical efficacy.
UAB researchers have created a 3D, three-layer nanomatrix vascular sheet that mimics human atherosclerosis, enabling high-throughput drug screening. The model replicates key features of the disease and has been validated with two classic atherosclerosis drugs.
Researchers at NTNU have developed a new method to study how bacterial signaling proteins react to treatment, paving the way for effective killing of MRSA. The method has shown a combination of two substances kills MRSA more effectively than when used separately.
Researchers at the University of Bath have created a novel bacterial system to mass-produce cyclic proteins and peptides, addressing a significant bottleneck in the development of new therapeutic treatments. By harnessing the natural cyclization process from the Oldenlandia flower, they improved heat and chemical stability, as well as ...
Researchers at the University of Pittsburgh have discovered a potential new target for treating Barth syndrome, a rare genetic disease with devastating consequences. They identified a molecular culprit that could be targeted to potentially reverse the disease course and developed a small-molecule drug candidate to correct genetic tafaz...
Researchers identified a promising dual-purpose target, KDM1A, using AI analysis of transcriptomic data from 16,740 healthy samples and 11,303 tumors. KDM1A was found to significantly extend lifespan in Caenorhabditis elegans and has anti-cancer activities established in preclinical and clinical studies.
Researchers have identified a small molecule that reverses four types of chronic pain in animal studies without troublesome side effects. The compound, CBD3063, binds to the inner region of a calcium channel, indirectly regulating its activity and reducing neurotransmitter release.
Researchers at the University of Illinois have developed a new antifungal molecule that targets fungal cells without harming human kidney cells or other tissues. The molecule, dubbed AM-2-19, has shown significant efficacy against various fungal infections in vitro and in vivo studies.
Scientists at Nagoya University developed a new gastric acid inhibitor with a binding affinity nearly 10 times higher than existing drugs. The AI-driven approach led to the creation of compound DQ-18, which exhibits stronger binding to the gastric proton pump.
A new international clinical trial found that a drug candidate is highly effective in treating Acanthamoeba keratitis with medical cure rates of 87%, reducing the risk of poor visual outcomes and surgery. The treatment, low concentration polihexanide (PHMB 0.08%), follows a novel and evidence-based protocol.
Researchers at Hokkaido University identified 2-thiouridine as a broad-spectrum antiviral drug candidate targeting ssRNA+ viruses. It inhibits viral replication and increases survival rates in mice models for dengue and COVID-19.
A promising drug candidate CDNF has been found to prolong the lifespan of ALS patients and alleviate symptoms in rats and mice. The study suggests that CDNF may rescue motoneurons by reducing ER stress response and cell death.
The US Army Medical Materiel Development Activity has developed a shelf-stable treatment for snakebite envenoming that is safe, easy to use, and independent of snake species. Clinical trials are ongoing in the US and India, with pre-clinical studies suggesting its potential use worldwide.
Researchers at Michigan Medicine have discovered a potential treatment for diffuse midline glioma, a type of childhood brain tumor with no effective treatments. The compound ONC201 nearly doubled survival rates in patients with the disease, and the underlying mechanism behind its success has been explained.
Researchers at TUM develop an RNA agent for a lung spray that slows macrophage activity, reducing lung inflammation and fibrosis. The active substance RCS-21 is delivered via an inhaler through a special sugar molecule, showing promise in treating acute inflammatory lung damage.
Researchers at UMass Amherst have discovered a potential new medical therapy for Lyme disease using lactate dehydrogenase inhibitors typically used to combat cancer. The study found that these inhibitors substantially impacted Borrelia burgdorferi growth, making them promising candidates against Lyme infections.
Researchers at Tokyo University of Science successfully synthesized tanzawaic acid B in large amounts, paving the way for new antibiotic development. The breakthrough method could lead to creation of various compounds for pharmaceuticals, including new antibiotic candidates.
Researchers at Uppsala University developed a modified lactic acid bacteria treatment that accelerated wound healing in humans. The study showed improved outcomes and safety with ILP100-Topical, a potential new treatment for complex and hard-to-heal wounds.
Researchers have engineered a new CRISPR-based drug candidate targeting E. coli directly while preserving the microbiome. The innovative treatment has shown promise in reducing E. coli burden in mice and is now in phase 1 clinical trials to treat blood cancer patients and prevent deadly infections.
Researchers at Nagoya University have successfully developed an ultrafast and simple synthetic method for producing indole derivatives. The new microflow synthesis method enables precise control of short reaction times, limiting unwanted dimerization/multimerization and increasing the yield of desired products.
TRIO Pharmaceuticals is developing a proprietary platform of dual-action tumor immunity-enhancing drugs aimed at treating cancers with high unmet medical needs. The company's innovative approach selectively eliminates immunosuppressive cells, enhancing antitumor activity.
Researchers have developed a glycine-based tripeptide that successfully treats nonalcoholic fatty liver disease in non-human primates and mice. The compound, DT-109, reverses fat buildup and prevents scarring by stimulating fatty acid degradation and antioxidant formation.
A team from Osaka University discovered that celastrol blocks the progression of rheumatoid arthritis by inhibiting a protein complex that promotes autoimmune responses. The researchers found that celestrol binds to COMMD3 covalently, preventing the formation of the COMMD3/8 complex and impairing antibody production.
A small molecule discovered by University of Houston researchers could potentially shorten the course of SARS-CoV-2 infection, offering a new alternative treatment option for COVID-19. The compound, CD04872SC, has shown promise in neutralizing the virus and its variants Delta and Omicron.
Researchers at Goethe University Frankfurt have identified nitroxoline as a potential treatment alternative for mpox. The antibiotic demonstrates effectiveness against both the current mpox virus and a tecovirimat-resistant strain, offering a promising solution to combat the outbreak.
Researchers used AI to analyze literature describing compounds that enhance mitophagy, a process damaged in Parkinson's disease. Probucol, a cholesterol-lowering drug, was identified as the most effective compound with improved motor function and neuron loss in animal models.
A study by Emory University researchers found that extracts from two wild plants, tall goldenrod and eagle fern, inhibited the ability of the SARS-CoV-2 virus to infect living cells. The active compounds are present in miniscule quantities, making it ineffective for self-treatment, but may hold promise as medicines against COVID-19.
A study identified an antibody candidate that blocks the protein VEGF-B, presenting a possible therapeutic option for fatty liver disease. The treatment method involves keeping fatty acids in adipose tissue to prevent liver accumulation.
Researchers found that plasma GH levels are a potential biomarker for predicting treatment outcomes in patients with advanced HCC treated with Atezo/Bev. The study showed significantly superior overall survival and non-significant trend in favor of GH-low patients compared to GH-high patients.